Pamalican Asset Management Ltd Makes New $341,000 Investment in Humacyte, Inc. (NASDAQ:HUMA)

Key Points

• Pamalican Asset Management Ltd has purchased **200,000 shares** of Humacyte, Inc. (NASDAQ:HUMA) valued at approximately **$341,000**, making it the fund's **8th largest position**.
• Humacyte's stock has been down **5.0%** and currently trades around **$2.28**, with a **market capitalization** of **$353.67 million**.
• The company reported earnings of **($0.10) per share**, beating estimates, with analysts forecasting a consensus rating of **"Moderate Buy"** and an average price target of **$11.71**.

Pamalican Asset Management Ltd bought a new stake in Humacyte, Inc. (NASDAQ:HUMA - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 200,000 shares of the company's stock, valued at approximately $341,000. Humacyte accounts for 0.5% of Pamalican Asset Management Ltd's investment portfolio, making the stock its 8th biggest position. Pamalican Asset Management Ltd owned 0.13% of Humacyte as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of HUMA. Woodline Partners LP boosted its position in shares of Humacyte by 235.7% during the fourth quarter. Woodline Partners LP now owns 2,848,802 shares of the company's stock worth $14,386,000 after buying an additional 2,000,268 shares during the period. CenterBook Partners LP purchased a new stake in Humacyte during the fourth quarter worth about $6,463,000. Brevan Howard Capital Management LP boosted its stake in shares of Humacyte by 2,795.1% in the fourth quarter. Brevan Howard Capital Management LP now owns 876,340 shares of the company's stock valued at $4,426,000 after purchasing an additional 846,070 shares during the period. Vanguard Group Inc. increased its stake in Humacyte by 10.8% during the 4th quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company's stock worth $28,294,000 after buying an additional 543,995 shares during the period. Finally, Franklin Resources Inc. purchased a new stake in Humacyte during the 4th quarter worth approximately $2,189,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Wall Street Zen downgraded shares of Humacyte from a "hold" rating to a "sell" rating in a research note on Friday, July 18th. D. Boral Capital reiterated a "buy" rating and issued a $25.00 price objective on shares of Humacyte in a research note on Wednesday, July 23rd. Benchmark cut their target price on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Finally, HC Wainwright assumed coverage on shares of Humacyte in a report on Wednesday, May 14th. They set a "buy" rating and a $4.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Humacyte currently has an average rating of "Moderate Buy" and a consensus price target of $11.71.

Humacyte Stock Performance

Humacyte stock traded down $0.10 during trading hours on Wednesday, reaching $2.22. 3,717,018 shares of the stock were exchanged, compared to its average volume of 3,749,442. Humacyte, Inc. has a 52-week low of $1.15 and a 52-week high of $8.72. The firm's 50 day moving average is $2.41 and its 200 day moving average is $2.59. The stock has a market cap of $343.59 million, a P/E ratio of -3.21 and a beta of 1.90. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.28 and a current ratio of 3.68.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.09. The business had revenue of $0.52 million during the quarter, compared to analyst estimates of $0.46 million. Analysts predict that Humacyte, Inc. will post -1.27 EPS for the current fiscal year.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.